The rebranding and ticker change are cosmetic and unlikely to drive material stock movement. Monitor CNSide test volume growth and payer expansion as leading indicators of revenue generation. The next catalyst is the SNO/ASCO CNS Metastases Conference in August 2026 and potential REYOBIQ Phase 2 data updates.
Price Chart
Executive Summary
Plus Therapeutics announced a corporate rebranding to Cerenome and a Nasdaq ticker change to CNSY effective August 3, 2026, alongside affirming 2026 milestones. The company reported commercial progress for its CNSide diagnostics platform, with 232 tests performed year-to-date and payer coverage expanding to ~126 million lives, but provided no financial results or guidance on revenue or earnings.
Key Facts
- Company name change from Plus Therapeutics to Cerenome, ticker change to CNSY effective August 3, 2026.
- Affirmed 2026 milestones including REYOBIQ pivotal-trial readiness, CNSide commercialization, and data/AI strategy.
- CNSide diagnostics: 232 tests performed year-to-date, June record of 72 tests; expects run rate of 1,250 tests per annum by end of 2026.
- Payer coverage expanded to ~126 million covered lives via agreements with Highmark, Blue Shield of California, and Elevance Health.
- CNSide received PTAN for Medicare claims submission; PLA Code 0640U effective July 1, 2026.
- REYOBIQ: ReSPECT-GBM enrolled 31 of 34 subjects; ReSPECT-LM expects optimal dose with 12-18 patients; ReSPECT-PBC first dosing expected Q3 2026.
- No financial results (revenue, EPS, guidance) were disclosed in the press release.
Financial Impact
No financial figures disclosed; commercial metrics suggest early-stage revenue potential from CNSide diagnostics but no dollar amounts provided.
Risk Factors
- No revenue or earnings disclosed; company remains pre-revenue with ongoing cash burn.
- REYOBIQ clinical trials may face delays or negative data; FDA interactions uncertain.
- CNSide commercial adoption may not sustain growth trajectory; reimbursement and pricing risks remain.
- Rebranding may cause short-term ticker confusion or liquidity shifts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319554 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers